ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

IU

Istanbul University Institute of Oncology at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Istanbul University Institute of Oncology takes part in 5 sessions at ESMO 2026 in Madrid. Its sessions examine treatment outcomes across gastrointestinal, breast, lung, gynecological, and skin cancers. They cover survival patterns in early-onset metastatic pancreatic cancer and recurrence in adult granulosa cell tumors.

OrganizationESMO 2026 Attendance
IU
Istanbul University Institute of Oncology
Istanbul, Türkiye
Cancer centre & hospital
Oncology institute in Istanbul, Türkiye.
Poster
Fri Oct 23
13:00–15:00
Clinical characteristics and survival outcomes in early-onset metastatic pancreatic cancer
ePoster session 17
Gastrointestinal cancers
Poster
Fri Oct 23
13:00–15:00
Clinical outcomes, recurrence patterns and prognostic factors in adult granulosa cell tumors: A single-center retrospective cohort
ePoster session 7
Gynaecological cancersSarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Evaluation of clinicopathological features and prognosis in patients with Merkel cell carcinoma
ePoster session 13
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
13:00–15:00

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Istanbul University Institute of Oncology

Tell us what you sell and we’ll find the people at Istanbul University Institute of Oncology most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction